<DOC>
	<DOCNO>NCT02637206</DOCNO>
	<brief_summary>GSK2894512 novel anti-inflammatory agent currently development topical treatment atopic dermatitis chronic plaque psoriasis . This study Phase I , single-center , randomize , partial-blinded ( evaluator blind ) study consist two part ( Part 1 2 ) . Part 1 study ass skin irritation follow single application GSK2894512 cream 2 concentration ( e.g . 0.5 % 1 % ) placebo simple-patch test photo-patch test semi-occlusive condition 20 healthy Japanese volunteer . Part 2 study ass skin irritation follow repeat application 0.5 % 1 % GSK2894512 cream placebo 7 day non-occlusive condition 6 healthy Japanese volunteer . The study Screening visit occur within 30 day Day 1 visit part . Eligible subject able participate either Part 1 Part 2 . Subjects visit site Day -1 , hospitalize end assessment Day 4 ( Part 1 ) Day 7 ( Part 2 ) . Subjects re-visit site Day 8 ( Part 1 ) Day 15 ( Part 2 ) follow-up assessment . This study first evaluate safety , tolerability pharmacokinetics GSK2894512 cream single repeat application Japanese subject . Results study enable clinical investigation Japanese population .</brief_summary>
	<brief_title>Skin Irritation Study GSK2894512 Cream</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Japanese male female age 20 64 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GlaxoSmithKline ( GSK ) Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Healthy skin potential test site back erythema dermal reaction easily visualize . Body Mass Index within range 18.5 24.9 kilogram per square meter ( kg/m^2 , inclusive ) less 25.0 kg/m^2 . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter estradiol &lt; 40 picograms per milliliter ( &lt; 147 picomole per liter ) . Capable give write informed consent , include compliance requirement restriction list consent form Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single QTc value : QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &lt; 450 millisecond ; QTcF &lt; 480 msec subject Bundle Branch Block . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History know suspect intolerance ingredient study product , adhesive tape/plaster , test patch . Subjects inherent sensitivity sun history photosensitivity . Inability evaluate skin around potential test sit back due sunburn , unevenness skin tone , tattoo , scar , excessive hair , freckle , birthmark , mole , skin damage abnormality . Clinicallyrelevant skin disease , include psoriasis , eczema , atopic dermatitis , acne , dysplastic nevus , skin pathology , history skin cancer , may , opinion investigator , contraindicate participation interfere test site evaluation . Considered immunocompromised , clinicallyrelevant history currently suffer disease condition , opinion investigator , might affect evaluation study product place subject undue risk . A positive prestudy syphilis , Hepatitis B surface antigen , Hepatitis C antibody , Human Immunodeficiency Virus antigen antibody Human Tcell Lymphotropic Virus1 result screening . A positive prestudy drug screen . The subject donate unit blood `` &gt; 400 milliliter ( mL ) '' within previous 4 month `` &gt; 200 mL '' within previous 1 month prior first dose day . The subject participate clinical study investigational noninvestigational drug device previous 4 month prior first dose day . Exposure four new chemical entity within 12 month prior first dose day . The subject plan concurrently participate another clinical study postmarketing study . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day prior first application study medication . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Healthy Japanese</keyword>
	<keyword>GSK2894512</keyword>
	<keyword>skin safety</keyword>
</DOC>